Close Menu

NEW YORK (GenomeWeb) – Deutsche Bank has initiated coverage on the life sciences and diagnostics sector, saying it is "generally positive" on the outlook for its fundamentals, even though company valuations are near historical highs, and assigned a Neutral outlook for the group of eight stocks.

Analyst Shawn Bevec assigned Buy ratings to shares of Fluidigm, Myriad Genetics, and Thermo Fisher Scientific, and Hold ratings to shares of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters. He also listed Myriad and Thermo Fisher as "top" picks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.